Intensity-modulated radiotherapy and involved-node concept in patients with Hodgkin lymphoma: Experience of the Gustave-Roussy Institute.;Optimisation de l'« involved-node radiotherapy » par l'utilisation de la modulation d'intensité dans le lymphome hodgkinien localisé: Expérience de l'institut Gustave-Roussy

Cancer/Radiotherapie

Volumn 15, Issue 8, 2011, Pages 709-715

  Paumier, A ^a   Khodari, W ^a   Beaudre, A ^a   Ghalibafian, M ^a   Blanchard, P ^a   Al Hamokles, H ^a   Bhari, M ^a   Lessard, N ^a   Girinsky, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Hodgkin lymphoma; IMRT; Intensity modulated radiation therapy; Involved node radiotherapy; Relapse; Toxicity

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; TREATMENT OUTCOME; ADOLESCENT; FEMALE; HEALTH CARE FACILITY; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; FEMALE; HEALTH FACILITIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 83155180187     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.05.014     Document Type: Article

References (43)

1. Bonadonna G., Bonfante V., Viviani S., Di Russo A., Villani F., Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004, 22:2835-2841.
2. Ferme C., Eghbali H., Meerwaldt J.H., Rieux C., Bosq J., Berger F., et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007, 357:1916-1927.
3. Noordijk E.M., Carde P., Dupouy N., Hagenbeek A., Krol A.D., Kluin-Nelemans J.C., et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006, 24:3128-3135.
4. Engert A., Franklin J., Eich H.T., Brillant C., Sehlen S., Cartoni C., et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007, 25:3495-3502.
5. Drouet F., Cahu X., Pointreau Y., Denis F., Mahé M.A. Lymphome de Hodgkin. Cancer Radiother 2010, 14:S198-S209.
6. Oeffinger K.C., Mertens A.C., Sklar C.A., Kawashima T., Hudson M.M., Meadows A.T., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
7. Girinsky T., Ghalibafian M. Radiotherapy of Hodgkin lymphoma: indications, new fields, and techniques. Semin Radiat Oncol 2007, 17:206-222.
8. Cosset J.M., Henry-Amar M., Girinski T., Malaise E., Dupouy N., Dutreix J. Late toxicity of radiotherapy in Hodgkin's disease. The role of fraction size. Acta Oncol 1988, 27:123-129.
9. Cosset J.M., Henry-Amar M., Pellae-Cosset B., Carde P., Girinski T., Tubiana M., et al. Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys 1991, 21:447-449.
10. Swerdlow A.J., Higgins C.D., Smith P., Cunningham D., Hancock B.W., Horwich A., et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007, 99:206-214.
11. Moser E.C., Noordijk E.M., van Leeuwen F.E., le Cessie S., Baars J.W., Thomas J., et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006, 107:2912-2919.
12. Hodgson D.C., Gilbert E.S., Dores G.M., Schonfeld S.J., Lynch C.F., Storm H., et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007, 25:1489-1497.
13. Ng A.K., Bernardo M.V., Weller E., Backstrand K., Silver B., Marcus K.C., et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100:1989-1996.
14. Engert A., Schiller P., Josting A., Herrmann R., Koch P., Sieber M., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003, 21:3601-3608.
15. Eich H.T., Diehl V., Gorgen H., Pabst T., Markova J., Debus J., et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010, 28:4199-4206.
16. Engert A., Plutschow A., Eich H.T., Lohri A., Dorken B., Borchmann P., et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010, 363:640-652.
17. Girinsky T., van der Maazen R., Specht L., Aleman B., Poortmans P., Lievens Y., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79:270-277.
18. Girinsky T., Specht L., Ghalibafian M., Edeline V., Bonniaud G., Van Der Maazen R., et al. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 2008, 88:202-210.
19. Girinsky T., Ghalibafian M., Paumier A. évolution et dilemmes dans les traitements du lymphome de Hodgkin. Cancer Radiother 2009, 13:479-481.
20. Girinsky T., Pichenot C., Beaudre A., Ghalibafian M., Lefkopoulos D. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006, 64:218-226.
21. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol Suppl 2005, 74:90-97.
22. Goodman K.A., Toner S., Hunt M., Wu E.J., Yahalom J. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 2005, 62:198-206.
23. Ghalibafian M., Beaudre A., Girinsky T. Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: dose constraints to virtual volumes or to organs at risk? Radiother Oncol 2008, 87:82-88.
24. Weber D.C., Peguret N., Dipasquale G., Cozzi L. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009, 75:1578-1586.
25. Mah D., Hanley J., Rosenzweig K.E., Yorke E., Braban L., Ling C.C., et al. Technical aspects of the deep inspiration breath-hold technique in the treatment of thoracic cancer. Int J Radiat Oncol Biol Phys 2000, 48:1175-1185.
26. Claude L., Malet C., Pommier P., Thiesse P., Chabaud S., Carrie C. Active breathing control for Hodgkin's disease in childhood and adolescence: feasibility, advantages, and limits. Int J Radiat Oncol Biol Phys 2007, 67:1470-1475.
27. Paumier A., Ghalibafian M., Beaudre A., Ferreira I., Pichenot C., Lefkopoulos D., et al. Involved node radiotherapy (INRT) and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011, 80:199-205.
28. Yahalom J., Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002, 13:79-83.
29. Girinsky T., Ghalibafian M., Bonniaud G., Bayla A., Magné N., Ferreira I., et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 2007, 85:178-186.
30. 18F)-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study. Int J Radiat Oncol Biol Phys 2011, 79:823-828.
31. Remonnay R., Morelle M., Giammarile F., Pommier P., Carrère M.O. L'apport de la tomographie par émission de positons au FDG pour la radiothérapie: résultats de l'évaluation économique du Stic « TEP et radiothérapie ». Cancer Radiother 2009, 13:313-317.
32. ICRU. Prescribing, recording and reporting photon-beam intensity modulated radiation therapy. Report 83, International Commission on Radiation Units and Measurements. Washington, DC; 2010.
33. Koh E.S., Sun A., Tran T.H., Tsang R., Pintilie M., Hodgson D.C., et al. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2006, 66:223-228.
34. Bortfeld T., Jiang S.B., Rietzel E. Effects of motion on the total dose distribution. Semin Radiat Oncol 2004, 14:41-51.
35. Aleman B.M., Girinsky T., van der Maazen R.W., Strijk S., Meijnders P., Bortolus R., et al. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884). Int J Radiat Oncol Biol Phys 2005, 63:1184-1190.
36. Eich H.T., Staar S., Gossmann A., Hansemann K., Skripnitchenko R., Kocher M., et al. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2004, 58:1121-1127.
37. Peters L.J., O'Sullivan B., Giralt J., Fitzgerald T.J., Trotti A., Bernier J., et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010, 28:2996-3001.
38. Liao Z.X., Komaki R.R., Thames H.D., Liu H.H., Tucker S.L., Mohan R., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:775-781.
39. Sura S., Gupta V., Yorke E., Jackson A., Amols H., Rosenzweig K.E. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 2008, 87:17-23.
40. Verbakel W.F., Senan S., Cuijpers J.P., Slotman B.J., Lagerwaard F.J. Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiother Oncol 2009, 93:122-124.
41. Travis L.B., Gilbert E. Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use. Radiat Res 2005, 163:695-696.
42. van Leeuwen F.E., Klokman W.J., Stovall M., Dahler E.C., van't Veer M.B., Noordijk E.M., et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95:971-980.
43. De Bruin M.L., Sparidans J., van't Veer M.B., Noordijk E.M., Louwman M.W., Zijlstra J.M., et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27:4239-4246.